Autolus Therapeutics (AUTL) Research & Development (2017 - 2025)
Historic Research & Development for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $27.9 million.
- Autolus Therapeutics' Research & Development fell 3082.86% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.9 million, marking a year-over-year decrease of 2222.75%. This contributed to the annual value of $138.4 million for FY2024, which is 609.67% up from last year.
- Autolus Therapeutics' Research & Development amounted to $27.9 million in Q3 2025, which was down 3082.86% from $27.4 million recorded in Q2 2025.
- Autolus Therapeutics' 5-year Research & Development high stood at $206.0 million for Q4 2021, and its period low was -$32.3 billion during Q3 2021.
- In the last 5 years, Autolus Therapeutics' Research & Development had a median value of $30.8 million in 2022 and averaged -$1.7 billion.
- Data for Autolus Therapeutics' Research & Development shows a peak YoY increase of 43189.68% (in 2021) and a maximum YoY decrease of 9636471.9% (in 2021) over the last 5 years.
- Autolus Therapeutics' Research & Development (Quarter) stood at $206.0 million in 2021, then plummeted by 96.34% to $7.5 million in 2022, then skyrocketed by 397.39% to $37.5 million in 2023, then fell by 17.88% to $30.8 million in 2024, then decreased by 9.53% to $27.9 million in 2025.
- Its Research & Development was $27.9 million in Q3 2025, compared to $27.4 million in Q2 2025 and $26.7 million in Q1 2025.